ML-210

• Description:

  ML-210 is a selective and covalent glutathione peroxidase 4 (GPX4) inhibitor with an EC50 of 30 nM. ML-210 binds the GPX4 selenocysteine residue. ML-210 has anti-cancer activity[1][2].

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H413

• Target:

  Ferroptosis; Glutathione Peroxidase

• Type:

  Reference compound

• Related Pathways:

  Apoptosis; Metabolic Enzyme/Protease

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/ml-210.html

• Purity:

  99.93

• Solubility:

  DMSO : 25 mg/mL (ultrasonic)

• Smiles:

  O=C (N1CCN (C (C2=CC=C (Cl) C=C2) C3=CC=C (Cl) C=C3) CC1) C4=NOC (C) =C4[N+] ([O-]) =O

• Molecular Formula:

  C22H20Cl2N4O4

• Molecular Weight:

  475.32

• Precautions:

  H302, H413

• References & Citations:

  [1]John K. Eaton, et al. Targeting a Therapy-Resistant Cancer Cell State Using Masked Electrophiles as GPX4 Inhibitors. Biorxiv. 2018.|[2]Weïwer M, et al. Development of small-molecule probes that selectively kill cells induced to express mutant RAS. Bioorg Med Chem Lett. 2012 Feb 15;22 (4) :1822-6.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  GPX4

• CAS Number:

  1360705-96-9